Clinical trials: Dementia Disorders
Dementia With Parkinson's Disease
The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia
A randomised, double-blind, 3-arm parallel group study comparing Aricept® with placebo.
- Trial name
- NCT00165815
- Testing
- ARICEPT
- Where
- 4 sites in Germany, Ireland
- Sponsor
- Eisai Limited
Alzheimer's Disease, Multiple Sclerosis
A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery
The purpose of this research project is to collect and store blood samples and clinical data. Researchers can then use the stored samples in future studies.
- Conditions
- Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease, Huntington's Disease
- Trial name
- NCT01592552
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Agitation in Patients With Dementia of the Alzheimer's Type
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
This was an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305.
- Trial name
- NCT02446132
- Testing
- AVP-786
- Where
- 227 sites in United States, Bulgaria and 8 more
- Volunteers
- 1,197 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease
Assessing Clinical Outcomes in Alzheimer's Disease Agitation
This is a multi-center, double-blind, placebo-controlled, randomized withdrawal study to evaluate the efficacy and safety of AXS-05 compared to placebo in the treatment of agitation symptoms in subjects with agitation associated…
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor
- Trial name
- ACCORD (NCT04797715)
- Testing
- AXS-05
- Where
- 63 sites in United States, Canada
- Volunteers
- 178 people
- Sponsor
- Axsome Therapeutics, Inc.
Alzheimer's Disease
SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease
An open-label, proof-of-concept study to evaluate the safety and treatment effects of SLS-005 in Participants with Alzheimer's Disease (AD) treated once or twice weekly for 52 weeks.
- Trial name
- [STRIVE-AD] (NCT05332678)
- Testing
- SLS-005 - Once Weekly, SLS-005 - Twice Weekly
- Where
- 3 sites in Australia
- Sponsor
- Seelos Therapeutics, Inc.
Pseudobulbar Affect (PBA), Stroke
Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)
The objectives of the study are to evaluate the safety, tolerability, and effectiveness of NUEDEXTA capsules containing 20 mg DM (Dextromethorphan)/10 mg Q (Quinidine) for treatment of Pseudobulbar Affect (PBA) in patients with…
- Conditions
- Pseudobulbar Affect (PBA), Stroke, Dementia, Traumatic Brain Injury (TBI)
- Trial name
- PRISM II (NCT01799941)
- Testing
- Nuedexta (DM 20 mg/Q 10 mg)
- Where
- United States
- Volunteers
- 367 people
- Sponsor
- Avanir Pharmaceuticals
Alzheimer Disease, Cognitive Impairment
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)
This is an open-label extension for a multicenter, randomized, double-blind, sham-controlled, adaptive design pivotal study. Participants who complete the Hope Study (CA-0011) will be eligible to consent for screening to enroll…
- Conditions
- Alzheimer Disease, Cognitive Impairment, Mild Cognitive Impairment, Dementia, Mild
- Trial name
- NCT06245031
- Testing
- Sensory Stimulation System (GS120) - Active
- Where
- 53 sites in United States
- Volunteers
- 402 people
- Sponsor
- Cognito Therapeutics, Inc.
Alzheimer's Disease
BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects
This is a randomized double-blind (investigator and subject blinded), placebo controlled ascending single dose study to evaluate the safety, tolerability, and pharmacokinetic profile of BPN14770 in healthy male and female…
- Trial name
- NCT02648672
- Testing
- BPN14770
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Tetra Discovery Partners
Respiratory Disease, Cardiovascular Diseases
Hospice Quality Score Assessment Post Pharmacist Intervention
The study aims to investigate the impact of pharmacist delivered interventions on hospice patients quality metric scores.
- Conditions
- Respiratory Disease, Cardiovascular Diseases, Neurologic Disorder, Dementia
- Trial name
- NCT04361669
- Testing
- Medication safety review
- Where
- United States
- Sponsor
- Tabula Rasa HealthCare
Alzheimer's Disease
A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease
This is a Phase II, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the effects of MABT5102A on brain amyloid burden (as assessed by amyloid PET imaging) and other biomarkers in patients with mild…
- Trial name
- NCT01397578
- Testing
- MABT5102A
- Where
- 29 sites in United States, France and 1 more
- Volunteers
- 91 people
- Sponsor
- Genentech, Inc.
Memory Impairment, Alzheimer's Disease
Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults
The purpose of this study is to determine whether scopolamine-induced cognitive impairment is attenuated by the administration of roflumilast in combination with donepezil.
- Trial name
- NCT02051335
- Testing
- Roflumilast, Donepezil, Scopolamine
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Alzheimer's Disease
A Study of Semorinemab in Patients With Moderate Alzheimer's Disease
This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the clinical efficacy, safety, pharmacokinetics, and pharmacodynamics of semorinemab in patients with moderate AD.
- Trial name
- NCT03828747
- Testing
- Semorinemab, [18F]GTP1
- Where
- 49 sites in United States, France and 2 more
- Volunteers
- 272 people
- Sponsor
- Genentech, Inc.
Alzheimer's Disease, Fronto-temporal Dementia
Pilot Trial Evaluating Patient Experience With the MemorEM for Patients With Neurological Diseases
Primary Objective: The primary objective of this pilot study is to gain voluntary feedback from patients with neurological diseases and their caregivers regarding their experiences using the MemorEM head device.
- Conditions
- Alzheimer's Disease, Fronto-temporal Dementia, Parkinson Disease (PD), Cortico Basal Degeneration
- Trial name
- NCT07049341
- Testing
- MemorEM
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- NeuroEM Therapeutics, Inc.
Healthy, Alzheimer's Disease
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY2599666 in different groups of people - those who are healthy, those who have mild cognitive impairment due to Alzheimer's…
- Conditions
- Healthy, Alzheimer's Disease, Mild Cognitive Impairment
- Trial name
- NCT02614131
- Testing
- LY2599666, Solanezumab
- Where
- 5 sites in United States, Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Huntington Disease
A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278
The study drug, GSK356278, is a possible new medicine for the treatment of Huntington's disease. Huntington's disease, which is often called HD, is caused by a faulty gene that is passed down through families.
- Trial name
- NCT01573819
- Testing
- GSK356278
- Where
- Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease
An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study
The primary objective of this open-label extension trial was to evaluate the long-term safety of AXS-05 for the treatment of Alzheimer's disease agitation in subjects that participated in ADVANCE-2 or ACCORD-2.
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor
- Trial name
- NCT06736509
- Testing
- AXS-05 (dextromethorphan-bupropion)
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 139 people
- Sponsor
- Axsome Therapeutics, Inc.
Alzheimer Disease
Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type
Safety and tolerability. Quality of life (EQ-5D, ACQLI) and health economic impact (health resource utilisation, living and employment status) assessments, will not be performed at the centers in the united kingdom (UK)
- Trial name
- NCT02248116
- Testing
- Talsaclidine
- Volunteers
- 198 people
- Sponsor
- Boehringer Ingelheim
Alzheimer Disease
A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
The main purpose of this study is to look at how safe the study drug (mevidalen) is and whether it works to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia.
- Trial name
- NCT06538116
- Testing
- Mevidalen
- Where
- 64 sites in United States, Japan
- Volunteers
- 304 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease, Huntington's Disease
A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects
This study is to characterize the pharmacokinetics of single and multiple oral doses of Dimebon in Japanese healthy subjects. This study is also to evaluate the safety and tolerability of single and multiple oral doses of Dimebon…
- Trial name
- NCT00825084
- Testing
- Dimebon
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimer Disease, Healthy Volunteers
A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease
This study is being done for the following reasons: To determine the safety of LY2886721 and any side effects that may be associated with it and to see how much of the study drug is in the blood and the cerebrospinal fluid (CSF)…
- Trial name
- NCT01807026
- Testing
- LY2886721
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.